{"id":"cd7-car-t-cells","safety":{"commonSideEffects":["Cytokine release syndrome","Neurotoxicity","Cytopenias"]},"_chembl":{"chemblId":"CHEMBL1605298","moleculeType":"Small molecule","molecularWeight":"354.36"},"modality":"Biologic","_dailymed":null,"mechanism":{"target":"CD7","explanation":"CD7 CAR T cells are engineered to recognize and bind to CD7, a surface protein highly expressed on T-cell malignancies. Upon binding, the CAR T cells become activated and destroy the CD7-expressing cancer cells through immune-mediated cytotoxicity.","oneSentence":"Genetically modified T cells that express a chimeric antigen receptor targeting CD7 on malignant T cells to eliminate cancer cells."},"_scrapedAt":"2026-03-28T05:57:40.181Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123263,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"CD7 CAR T cells","brand":null,"company":"Baylor College of Medicine","rationale":"Academic CD7-targeted CAR T cell therapy for T-cell malignancies"},{"name":"CD5 CAR T cells","brand":null,"company":"Baylor College of Medicine","rationale":"Alternative CAR T approach targeting different T-cell antigen"}],"description":"CD7 CAR T cells are an investigational cell therapy being developed by iCell Gene Therapeutics for the treatment of T-cell malignancies. This therapy involves genetically engineering a patient's T cells to express a chimeric antigen receptor targeting CD7, a protein expressed on malignant T cells.","indications":{"approved":[{"status":"investigational","condition":"T-cell acute lymphoblastic leukemia","patientPopulation":"Adult and pediatric, relapsed/refractory"},{"status":"investigational","condition":"T-cell lymphoblastic lymphoma","patientPopulation":"Adult and pediatric, relapsed/refractory"}]},"trialDetails":[{"nctId":"NCT07476027","phase":"EARLY_PHASE1","title":"Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-15","conditions":"T Lymphoblastic Lymphoma, T Acute Lymphoblastic Leukemia","enrollment":10},{"nctId":"NCT05909527","phase":"PHASE1, PHASE2","title":"A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma","status":"WITHDRAWN","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2023-05-01","conditions":"T-Cell Acute Lymphocytic Leukemia","enrollment":""},{"nctId":"NCT07220993","phase":"PHASE1","title":"Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-06","conditions":"T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia","enrollment":27},{"nctId":"NCT05895994","phase":"EARLY_PHASE1","title":"Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"MEI HENG","startDate":"2023-03-10","conditions":"Neoplasms, Hematologic Neoplasms, Neoplasms by Site","enrollment":2},{"nctId":"NCT07345780","phase":"NA","title":"Clinical Study on the Safety and Efficacy of CD7-Targeted Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for the Treatment of CD7-Positive Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Donghua Zhang","startDate":"2026-12-31","conditions":"CD7-Positive Hematological Malignancies","enrollment":28},{"nctId":"NCT07338604","phase":"EARLY_PHASE1","title":"Clinical Study of UTAA07 Injection in the Treatment of Hematologic and Lymphatic Systemic Malignancies","status":"RECRUITING","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2025-12-12","conditions":"Hematolymphoid Malignancies","enrollment":15},{"nctId":"NCT06514794","phase":"PHASE2","title":"A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)","status":"RECRUITING","sponsor":"Wugen, Inc.","startDate":"2025-01-31","conditions":"T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":125},{"nctId":"NCT06934382","phase":"PHASE1","title":"Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Stephan Grupp MD PhD","startDate":"2025-04-29","conditions":"T-Cell Acute Lymphoblastic Leukemia/Lymphoma","enrollment":33},{"nctId":"NCT07153068","phase":"PHASE1, PHASE2","title":"SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML)","enrollment":12},{"nctId":"NCT07280494","phase":"PHASE1","title":"To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-18","conditions":"CD7+ T-ALL/LBL","enrollment":18},{"nctId":"NCT07188610","phase":"PHASE2","title":"PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2025-09-25","conditions":"CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma","enrollment":100},{"nctId":"NCT06064903","phase":"PHASE1, PHASE2","title":"CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL","status":"RECRUITING","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2024-04-21","conditions":"T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma","enrollment":26},{"nctId":"NCT06316427","phase":"PHASE1, PHASE2","title":"Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2024-03-22","conditions":"T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT07244380","phase":"PHASE2","title":"Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2025-11-28","conditions":"T Lymphoblastic Leukemia/Lymphoma","enrollment":38},{"nctId":"NCT03690011","phase":"PHASE1","title":"Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2021-08-02","conditions":"T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia","enrollment":27},{"nctId":"NCT07201727","phase":"EARLY_PHASE1","title":"CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-30","conditions":"AML - Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT04984356","phase":"PHASE1","title":"A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL","status":"COMPLETED","sponsor":"Wugen, Inc.","startDate":"2022-01-14","conditions":"T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":28},{"nctId":"NCT07109518","phase":"PHASE1","title":"uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-28","conditions":"Acute Myeloid Leukemia (AML), T Lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT07143929","phase":"PHASE1","title":"To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-08-18","conditions":"CD7 Positive R/R PTCL","enrollment":18},{"nctId":"NCT07142161","phase":"EARLY_PHASE1","title":"A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2025-07-20","conditions":"Type 1 Diabetes","enrollment":3},{"nctId":"NCT07139600","phase":"","title":"Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2024-08-01","conditions":"Aplastic Anaemia, CAR-T, CD7 Positive","enrollment":5},{"nctId":"NCT05827835","phase":"PHASE1, PHASE2","title":"CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-04-30","conditions":"Hematologic Diseases, Neoplasms","enrollment":30},{"nctId":"NCT07120607","phase":"PHASE1","title":"Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-18","conditions":"Leukemia","enrollment":9},{"nctId":"NCT07117305","phase":"PHASE1, PHASE2","title":"CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Zhengzhou University","startDate":"2025-09-01","conditions":"CD7+ Lymphoma, T Cell Lymphoma","enrollment":38},{"nctId":"NCT06622694","phase":"PHASE1","title":"CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-06-19","conditions":"Severe Aplastic Anemia, Relapse, Refractory","enrollment":15},{"nctId":"NCT07022964","phase":"PHASE1, PHASE2","title":"CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-06-01","conditions":"T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)","enrollment":36},{"nctId":"NCT07008872","phase":"NA","title":"CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Qi deng","startDate":"2025-06-01","conditions":"CD7+ Lymphoma, CD7+ Acute Leukemia","enrollment":40},{"nctId":"NCT05290155","phase":"PHASE1","title":"Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-05-04","conditions":"T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia, Peripheral T Cell Lymphoma","enrollment":14},{"nctId":"NCT04689659","phase":"PHASE2","title":"Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma","status":"COMPLETED","sponsor":"Beijing Boren Hospital","startDate":"2021-12-01","conditions":"T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Relapse/Recurrence","enrollment":55},{"nctId":"NCT06849401","phase":"EARLY_PHASE1","title":"The Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-07","conditions":"T-ALL","enrollment":9},{"nctId":"NCT06925464","phase":"PHASE1, PHASE2","title":"CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-04-01","conditions":"T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)","enrollment":36},{"nctId":"NCT05377827","phase":"PHASE1","title":"Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-10-10","conditions":"T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma","enrollment":6},{"nctId":"NCT05454241","phase":"PHASE2","title":"CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-09-07","conditions":"Hematological Malignancies","enrollment":14},{"nctId":"NCT06871644","phase":"NA","title":"Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2025-03-18","conditions":"Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria","enrollment":18},{"nctId":"NCT06787560","phase":"EARLY_PHASE1","title":"CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-01-31","conditions":"Bone Marrow Failure Syndrome","enrollment":20},{"nctId":"NCT06769191","phase":"EARLY_PHASE1","title":"Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-01-30","conditions":"Schimke Immuno-osseous Dysplasia","enrollment":20},{"nctId":"NCT05885464","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beam Therapeutics Inc.","startDate":"2023-05-25","conditions":"Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT06758713","phase":"PHASE1","title":"Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies","status":"RECRUITING","sponsor":"The Third Affiliated Hospital of Southern Medical University","startDate":"2025-01-15","conditions":"Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy","enrollment":60},{"nctId":"NCT06732492","phase":"PHASE1","title":"RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-10-31","conditions":"NK T-Cell Lymphoma, CART Therapy, CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies","enrollment":10},{"nctId":"NCT06720324","phase":"PHASE1, PHASE2","title":"CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-12-31","conditions":"Hematologic Malignancy","enrollment":80},{"nctId":"NCT05923541","phase":"EARLY_PHASE1","title":"RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2023-06-26","conditions":"Hematologic Malignancies","enrollment":6},{"nctId":"NCT05902845","phase":"EARLY_PHASE1","title":"RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL","status":"COMPLETED","sponsor":"Xiaoyu Zhu","startDate":"2023-04-30","conditions":"Neoplasms, Hematologic Neoplasms, Hematologic Diseases","enrollment":4},{"nctId":"NCT05716113","phase":"EARLY_PHASE1","title":"CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL","status":"COMPLETED","sponsor":"He Huang","startDate":"2023-02-09","conditions":"Neoplasms, Hematologic Neoplasms, Neoplasms by Site","enrollment":20},{"nctId":"NCT05907603","phase":"EARLY_PHASE1","title":"Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)","status":"COMPLETED","sponsor":"Kai Lin Xu，MD","startDate":"2023-03-08","conditions":"Neoplasms, Hematologic Neoplasms, Hematologic Diseases","enrollment":8},{"nctId":"NCT05509855","phase":"","title":"A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007","status":"ENROLLING_BY_INVITATION","sponsor":"Wugen, Inc.","startDate":"2022-08-22","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma","enrollment":44},{"nctId":"NCT04840875","phase":"PHASE1","title":"Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma","status":"COMPLETED","sponsor":"Beijing Boren Hospital","startDate":"2021-09-14","conditions":"T Cell Lymphoma, T-cell Leukemia","enrollment":16},{"nctId":"NCT06420076","phase":"PHASE1, PHASE2","title":"Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2024-07-10","conditions":"T Cell Lymphoma, T Cell Leukemia, T-cell Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT06633328","phase":"EARLY_PHASE1","title":"CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2024-10-20","conditions":"Aplastic Anemia","enrollment":30},{"nctId":"NCT06585345","phase":"PHASE1, PHASE2","title":"Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia","status":"RECRUITING","sponsor":"The General Hospital of Western Theater Command","startDate":"2024-02-18","conditions":"Acute-Leukemia","enrollment":200},{"nctId":"NCT04938115","phase":"NA","title":"Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia","status":"COMPLETED","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2021-05-10","conditions":"Leukemia, T Cell","enrollment":50},{"nctId":"NCT04599556","phase":"PHASE1","title":"Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2021-04-01","conditions":"CD7+ Acute Leukemia, CD7+ Lymphoma","enrollment":81},{"nctId":"NCT06136364","phase":"PHASE1","title":"CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study","status":"RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2023-08-15","conditions":"T-lymphoblastic Lymphoma, T-ALL","enrollment":9},{"nctId":"NCT05995028","phase":"PHASE1","title":"Universal 4SCAR7U Targeting CD7-positive Malignancies","status":"RECRUITING","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2023-10-31","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT05979792","phase":"EARLY_PHASE1","title":"Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma","status":"UNKNOWN","sponsor":"Zhao Weili","startDate":"2023-09-01","conditions":"Peripheral T Cell Lymphoma","enrollment":35},{"nctId":"NCT04916860","phase":"NA","title":"Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"UNKNOWN","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2021-01-27","conditions":"SenL-T7 CAR T Cells for CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","enrollment":100},{"nctId":"NCT05513612","phase":"PHASE1","title":"Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies","status":"WITHDRAWN","sponsor":"Shanghai Pudong Hospital","startDate":"2020-08-01","conditions":"Acute Myeloid Leukemia (AML), B-cell Non-Hodgkin's Lymphoma (B-NHL), Multiple Myeloma (MM)","enrollment":""},{"nctId":"NCT04860817","phase":"EARLY_PHASE1","title":"A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL","status":"WITHDRAWN","sponsor":"920th Hospital of Joint Logistics Support Force of People's Liberation Army of China","startDate":"2021-12-01","conditions":"T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma","enrollment":""},{"nctId":"NCT05626400","phase":"NA","title":"Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL","status":"RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2022-08-29","conditions":"T-cell Acute Lymphoblastic Leukemia/Lymphoma","enrollment":100},{"nctId":"NCT05620680","phase":"NA","title":"CD7 CAR-T Cells in T-cell Lymphoma/Leukemia","status":"RECRUITING","sponsor":"Shenzhen University General Hospital","startDate":"2022-10-01","conditions":"T Lymphoblastic Leukemia/Lymphoma","enrollment":20},{"nctId":"NCT05170568","phase":"PHASE1","title":"PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2021-12-01","conditions":"CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies","enrollment":22},{"nctId":"NCT05554575","phase":"PHASE1","title":"Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL","status":"UNKNOWN","sponsor":"Bioceltech Therapeutics, Ltd.","startDate":"2022-10","conditions":"T Cell Lymphoblastic Lymphoma","enrollment":15},{"nctId":"NCT05528887","phase":"PHASE1","title":"Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2021-09-16","conditions":"Relapsed/Refractory Hematological Malignancies, Lymphoma, Myeloma","enrollment":10},{"nctId":"NCT05212584","phase":"PHASE1","title":"CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma","status":"UNKNOWN","sponsor":"iCell Gene Therapeutics","startDate":"2022-07-01","conditions":"Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma","enrollment":24},{"nctId":"NCT05398614","phase":"PHASE1","title":"SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies","status":"UNKNOWN","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2022-05-01","conditions":"T-ALL, Lymphoma, T-Cell","enrollment":18},{"nctId":"NCT04928105","phase":"NA","title":"Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma","status":"UNKNOWN","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2021-01-27","conditions":"Lymphoma, T-Cell","enrollment":100},{"nctId":"NCT04823091","phase":"PHASE1","title":"Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-04-15","conditions":"T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT05239702","phase":"EARLY_PHASE1","title":"Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2022-02-28","conditions":"Crohn Disease, Ulcerative Colitis, Dermatomyositis","enrollment":75},{"nctId":"NCT04538599","phase":"PHASE1","title":"RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies","status":"COMPLETED","sponsor":"He Huang","startDate":"2020-09-10","conditions":"Hematologic Malignancies","enrollment":12},{"nctId":"NCT05127135","phase":"PHASE1","title":"Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies","status":"UNKNOWN","sponsor":"Fundamenta Therapeutics, Ltd.","startDate":"2020-01-22","conditions":"T-Acute Lymphoblastic Leukemia, T-cell Non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Lymphoma","enrollment":30},{"nctId":"NCT05059912","phase":"PHASE2","title":"CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-08-05","conditions":"Refractory and Relapsed T Cell Lymphoma","enrollment":20},{"nctId":"NCT05043571","phase":"PHASE1","title":"CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2021-09-08","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute Adult","enrollment":20},{"nctId":"NCT04572308","phase":"PHASE1","title":"Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells","status":"COMPLETED","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2020-10-01","conditions":"T-cell Acute Lymphoblastic Leukemia/Lymphoma","enrollment":20},{"nctId":"NCT04264078","phase":"EARLY_PHASE1","title":"Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2021-03-01","conditions":"T-cell Leukemia, T-cell Lymphoma","enrollment":30},{"nctId":"NCT04934774","phase":"PHASE1","title":"Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances","status":"UNKNOWN","sponsor":"iCell Gene Therapeutics","startDate":"2020-12-01","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, T-cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT04762485","phase":"PHASE1, PHASE2","title":"Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-06-01","conditions":"T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04702841","phase":"EARLY_PHASE1","title":"CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2020-06-03","conditions":"CAR, Malignant Tumors","enrollment":8},{"nctId":"NCT04785833","phase":"NA","title":"CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2021-03-04","conditions":"T-ALL","enrollment":20},{"nctId":"NCT04480788","phase":"PHASE1","title":"CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2020-11-24","conditions":"T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type, Peripheral T-cell Lymphoma, Nonspecific","enrollment":9},{"nctId":"NCT04620655","phase":"NA","title":"RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL","status":"UNKNOWN","sponsor":"Min Xiang","startDate":"2020-11-15","conditions":"T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma","enrollment":24},{"nctId":"NCT04004637","phase":"PHASE1","title":"CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia","status":"UNKNOWN","sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","startDate":"2019-08-25","conditions":"T-lymphoblastic Lymphoma, NK/T Cell Lymphoma, Acute Lymphocytic Leukemia","enrollment":10},{"nctId":"NCT04033302","phase":"PHASE1, PHASE2","title":"Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies","status":"UNKNOWN","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2019-09-01","conditions":"T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"CD7 CAR T cells","genericName":"CD7 CAR T cells","companyName":"iCell Gene Therapeutics","companyId":"icell-gene-therapeutics","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}